BMY vs LLY
BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | BMY | LLY | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $67.28 | $1,246.93 | |
| Market cap as of 2026-08-25 | $137.4B | $1.17T | |
| P/E as of 2026-08-25 | 14.21 | 43.17 | BMY lower |
| PEG as of 2026-08-25 | -8.67 | 1.48 | BMY lower |
| Net margin as of 2026-08-25 | +18.9% | +33.5% | LLY higher |
| Gross margin as of 2026-08-25 | +71.7% | +83.4% | LLY higher |
| Operating margin as of 2026-08-25 | +25.5% | +42.2% | LLY higher |
| ROE as of 2026-08-25 | +46.8% | +92.6% | LLY higher |
| ROA as of 2026-08-25 | +10.3% | +22.0% | LLY higher |
| Debt / equity as of 2026-08-25 | 1.93 | 1.62 | LLY lower |
| Revenue growth (YoY) as of 2026-08-25 | +3.1% | +49.6% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | +31.7% | LLY higher |
| Dividend yield as of 2026-08-25 | +4.6% | +0.8% | BMY higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-25 | 0.18 | 0.46 | |
| 1-year return as of 2026-08-24 close | +40.4% | +75.2% | LLY higher |
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.